{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(4)"],"submitter":["Chai KL"],"pubmed_abstract":["Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few real-world data exist on its use in patients with myeloma. We investigated immunoglobulin use in Australia, New Zealand and Asia-Pacific using registry data and explored its association with survival outcomes. A total of 2374 patients with a median follow-up time of 29.5 months (interquartile range 13.3-54.3 months) were included in the analysis - 1673 from Australia, 313 Korea, 281 New Zealand and 107 Singapore. Overall, 7.1% of participants received immunoglobulin replacement within 24 months of diagnosis. Patients who received immunoglobulin replacement "],"journal":["EJHaem"],"pagination":["690-697"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11327709"],"repository":["biostudies-literature"],"pubmed_title":["Variation in immunoglobulin use and impact on survival in myeloma."],"pmcid":["PMC11327709"],"pubmed_authors":["Chng WJ","Moore EM","Augustson BM","McCaughan GJ","Kim K","Yoon SS","Harrison SJ","Tso AC","Thao L","Murphy N","Wong KS","Tan XN","Cooke R","Wellard C","King T","Hocking J","McQuilten ZK","Aoki N","Morrissey CO","Forsyth CJ","Mollee P","Wood EM","Spencer A","Goh YT","Kim JS","Quach H","Hamad N","Kerridge I","Chai KL","Blacklock H","Ho PJ","Bapat A"],"additional_accession":[]},"is_claimable":false,"name":"Variation in immunoglobulin use and impact on survival in myeloma.","description":"Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few real-world data exist on its use in patients with myeloma. We investigated immunoglobulin use in Australia, New Zealand and Asia-Pacific using registry data and explored its association with survival outcomes. A total of 2374 patients with a median follow-up time of 29.5 months (interquartile range 13.3-54.3 months) were included in the analysis - 1673 from Australia, 313 Korea, 281 New Zealand and 107 Singapore. Overall, 7.1% of participants received immunoglobulin replacement within 24 months of diagnosis. Patients who received immunoglobulin replacement ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-19T14:50:30.802Z","creation":"2025-04-19T14:50:30.802Z"},"accession":"S-EPMC11327709","cross_references":{"pubmed":["39157592"],"doi":["10.1002/jha2.938"]}}